Offstream
news

Health Canada authorizes the use of the AstraZeneca's antibody-based therapy Evushield for immunocompromised patients aged above 12 years.
2022-04-14

The Canadian government signs an agreement with AstraZeneca to procure 100,000 doses of the Evushield COVID-19 antibody therapy for use in high-risk patients.
2022-02-23

Georgia receives 43,200 doses of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford.
2021-07-10

Yemen begins their COVID-19 vaccination campaign using the vaccine produced by AstraZeneca and the University of Oxford.
2021-04-20

Italy invokes the European Union powers to block shipment of 250,700 doses of the Oxford–AstraZeneca vaccine to Australia amid escalations between the bloc and AstraZeneca. The European Commission endorses the move.
2021-03-4

Kyrgyzstan is expected to receive 504,000 doses of the Oxford-AstraZeneca vaccine in March.
2021-02-2

The Indian government announces that the country will speed up their reviews of vaccines developed by Pfizer and AstraZeneca.
2020-12-7

AstraZeneca is expected to resume vaccine trials in the United States as early as this week.
2020-10-20

AstraZeneca CEO Pascal Soriot says that the vaccine results could be ready by the end of the year if trials resume. Clinical trials were temporarily suspended after a participant in the trials began to develop symptoms associated with transverse myelitis.
2020-09-10

Bloomington-based HealthPartners announces that they are seeking 1,500 patients for the phase 3 trials for AstraZeneca's COVID-19 vaccine.
2020-09-2